Introduction Coronary heart disease (CHD) remains a leading cause of UK mortality. Dietary trans fats (TFA) represent a powerful CHD risk factor. However, UK efforts to reduce intake have been less successful than other nations. We modelled the potential health and economic effects of eliminating industrial and all TFA up to 2020. Elimination of all TFA would double the health and economic gains.
Introduction
Cardiovascular disease (CVD) (coronary heart disease (CHD) and stroke) continues to be a major cause of mortality and morbidity in the UK, and globally. Mortality rates for CVD have halved over the past two decades, 1 but despite this, approximately 35% of total UK deaths remain attributable to CVD. CVD is estimated to cost the UK economy £30 billion annually 2 with some £14 billion of this spent on healthcare. CHD costs have increased from £1.75 billion in 1999 to £2 billion in 2005, 3 with the statin bill alone exceeding £840 million in 2006, 4 while statin prescriptions had increased by almost 50% by 2012. 5 These costs are expected to continue to increase in the coming decades. Major risk factors for CHD are diet, smoking, alcohol excess and physical inactivity. 6 Within diet, key factors include suboptimal fruit and vegetable intake, excess salt, sugar, saturated fats and trans fatty acids (TFA). TFA are more harmful to CHD than any other macronutrient. TFA consumption comprises industrial TFA (approximately 0.8% daily energy intake in the UK) and ruminant TFA (approximately 0.4% daily energy intake). Industrial TFA are unsaturated fatty acids with at least one double bond in the trans configuration, formed during the partial hydrogenation of vegetable oils. This process is utilized in the production of margarines, commercial cooking and food manufacturing processes. The partial hydrogenation process converts the vegetable oil into a solid fat with stability during packing, enhanced palatability and longer shelf life, hence profitability. The major sources of dietary TFA in the UK are bakery products, spreads, packaged snack foods and deep-fried fast foods. Naturally occurring ruminant TFA, such as in meat, dairy and other ruminant products are produced by the action of bacteria in the ruminant stomach. The role of ruminant TFA upon CHD risk is much less well characterized than industrial TFA; initially thought to be relatively harmless, it now appears that this may have been under estimated owing to low intake levels. 7 Industrial TFA substantially increase CHD risk by raising LDL-cholesterol (bad cholesterol), reducing HDLcholesterol (good cholesterol), causing systemic inflammation and adversely affecting endothelial cell function. 8 TFA increase CHD risk more than any other macronutrient, 7 whereby every 1% increase in daily energy obtained from TFA raises CHD mortality by 12%. 8 Consumption of TFA has fallen across the developed world over the past decade, reaching approximately 0.8% (2 g) 9 of daily energy intake in the UK. This reduction has only been achieved by sustained pressure from the UK Food Standards Agency, reformulation efforts by some companies and voluntary content labelling. 10 The effectiveness of these voluntary measures appears to be decreasing given the decline in the rate of TFA intake reduction since 2007. 11 Labelling is probably not the answer-being slow, bureaucratic and of limited effectiveness. 12 Several other policies, ranging in efficacy, have been utilized to successfully reduce dietary TFA in countries across the globe. These include voluntary self regulation, and local or national legislation. 13 TFA bans in restaurant food in New York City eventually led to national-wide reformulation and a halving of population TFA levels in the USA, 11 however, can have inequitable effects. 13 The most effective policies have been national legislative bans, such as those seen in Denmark, Iceland, Austria and Switzerland. Moreover, we recently quantified the potential health effects upon the England and Wales population of reductions in TFA intake by 0.5% and 1% of daily energy intake, respectively. This demonstrated substantial potential health benefits of a reduction in TFA intake by 1%, including saving approximately 10 000 hospital admissions annually.
14 This also demonstrated large potential reductions in pre-existing inequalities within the CHD burden. 15 With scarce resources, the economic potential of prevention policies is increasingly important. We therefore aimed to quantify the potential health effects, costs and benefits of two potential UK-wide policies: elimination of industrial TFA only or complete elimination (industrial and natural) of dietary intake of TFA, to better inform policymakers.
Methods

IMPACTecon model
We modelled the potential health and economic effects of elimination of all TFA, industrial and ruminant (reducing intake to 0%) and elimination of industrial TFA (achieving intake of 0.4% daily energy) from 2011 to 2020 in the UK. Outputs include Deaths Prevented or Postponed (DPPs), Life Years Gained (LYGs), hospital admissions and a societal economic perspective inclusive of direct healthcare and informal care costs and averted productivity loss. Industry costs are also estimated and modelled, while state costs in implementing and monitoring such policies are also accounted for. Outputs are stratified by age, gender and socioeconomic circumstance (SEC). To create the IMPACTecon model, we extended the recently described IMPACTtfa model 14 calibrated for the English and Welsh population, to estimate the economic costs and benefits of both scenarios. Briefly, the IMPACTtfa model projects the expected number of deaths in 2011-2020 and then estimates the DPPs for a given reduction in TFA intake across the population. The effect size of TFA upon CHD mortality was taken from Mozaffarian et al. 8 Using the calculated DPPs, we calculated a reduction in hospital admissions and LYGs by multiplying DPPs by age, gender and CHD sub group-specific median survivals. Sub group-specific median survival estimates were obtained from previous analysis [16] [17] [18] [19] and updated with more recent data. 20 The resulting number of surviving patients in each scenario was calculated from the mortality reduction percentage of each given reduction in TFA intake and existing incidence numbers by disease group. The relative distribution and ratios of patients across the disease groups within the underlying burden remained consistent from 2007. 15 We conservatively assumed a negligible effect upon case fatality itself, hence negligible effect upon underlying community prevalence.
Data sources for the IMPACTecon model
The population was stratified into three age groups (<55, 55-74 and 75+), gender and SEC (five quintiles based on Index of Multiple Deprivation (IMD) scores, SEC 1 most affluent, SEC 5 most deprived). Mortality and demographic data for the IMPACT model was obtained from the ONS. Patient numbers were estimated for three mutually exclusive patient groups: acute myocardial infarction (AMI), unstable angina (UA) and heart failure (HF) admissions. CHD prevalence was not included. We used Hospital Episodes Statistics, Myocardial Ischaemia National Audit Project and the General Practice Research Database. Intake levels of TFA were taken from the National Diet & Nutrition Survey 9 and Low Income Diet and Nutrition Survey. 21 We also used specific mortality reductions for a given reduction in TFA intake 8 stratified into age-and sex-specific mortality reductions. 22 Further details on IMPACT data sources and methodology can be obtained from Bajekal et al. 23 and Supplementary data.
We modelled four scenarios outlined in Table 1 .
Cost-effective analysis
The monetary analysis takes a societal perspective, considering the state, industry, healthcare and wider economy monetary costs and benefits of the scenarios modelled.
State costs
We used costs relating to state monitoring of salt content as a best estimate. This was £2.4 million annually, comprising monitoring label contents and urine analysis of salt content. 24 For initial costs, we used a range with best estimate of £3 million (minimum: £100 000; maximum: £5 million).
Industry costs
The UK Food Standard Agency's Impact Assessment 2009 for the voluntary reformulation strategy suggests £25 000 reformulation cost per product (British Retail Consortium). Reformulation of TFA would affect 8000 product lines. 25 However, experience of TFAs regulation in other nations suggests that reformulation costs to industry are likely to be negligible. 26 We therefore modelled:
• Worst case-reformulation of 8000 product lines at £25 000/product.
• Best case-negligible reformulation cost (phased implementation hence absorbed into product's natural reformulation cycle).
An estimated ongoing annual cost of £2 million (1% maximum total capital spend) to (conservatively) account for reduced industry profits was included (Table 8) .
Direct healthcare savings
Costs were assigned to each treatment using data from the Department of Health reference costs 2010/11 and The Unit Costs of Health and Social Care 2011. 27 Observed treatment uptake rates were then used to calculate the unit cost for each patient group.
Productivity loss averted
This was calculated using frictional unemployment theory described by Liu et al. 28 This estimates the period of employees' absence from work before being replaced -90 days in the UK, 28 with mean hourly wage, 29 hours worked and the reduction in hospital admissions for each given year to calculate the potential reduction in lost productivity over the period.
Informal care costs CHD informal care costs were estimated by using the informal care costs in the British Heart Foundation CVD report of £1.9 billion 4 as a baseline. We reduced this sum by the corresponding proportional reduction of CHD incidence observed.
Outcomes were discounted at 3.5% as per NICE guidelines. Table 2 . Baseline scenario for comparison over this 10-year period was no legislative action on TFA, assuming that CHD mortality would continue to reduce at the rate from 1999 to 2007. 15 
Uncertainty analysis
We conducted a probabilistic sensitivity analysis for parameter uncertainty with 10 000 Monte Carlo simulation iterations. This is outlined in Supplementary data.
Results
Health outcomes
Elimination of all TFA resulted in the largest mortality and LYG, with slightly larger gains when modelling unequal baseline TFA by SEC. CHD SEC inequalities had larger reductions assuming unequal baseline intake. (Table 3) . Total hospital admissions averted over the 10-year period would be approximately 68 000. (Table 3) . Total hospital admissions averted would be approximately 38 000.
Scenario 2 (Elimination of all TFA, unequal intake)
This scenario could prevent approximately 3300 deaths per year (3141-3540), gaining approximately 29 000 life years (26 257-31 903). This could also result in approximately 8400 fewer hospital admissions (3258-13 439) (Table 3). Total hospital admissions averted over the period would be approximately 72 000. Scenario 3 (Elimination of industrial TFA, equal intake) This scenario could prevent approximately 1600 deaths per year (1521-1714), gaining approximately 14 000 life years (12 291-14 984). This could also result in approximately 4000 fewer hospital admissions (−1355 to 9215) (
Socioeconomic inequalities
The above potential health gains resulting from elimination of all TFA could reduce existing health inequalities. Conservatively estimating assuming equal intake of TFA, approximately 40% more DPPs and 80% more LYGs would be gained in the most deprived compared with the most affluent. When modelling a more realistic scenario (unequal 
Costs
Total state costs could range from £22 to £27.2 million over the 10-year period, with initial legislative costs ranging from £100 000 to £5 million (Table 4 ). Table 5 demonstrates that between approximately £95 million (95% CI: £64-£125 million) to £201 million (£139-£262 million) could be saved in direct healthcare costs as a result of reduced hospital admissions 2011-2020. However, financial savings to the wider economy could be substantially larger. Between approximately £368 million (£249-£481 million) and £727 million (£598-£880 million) could be saved in informal care costs (Table 6) , whilst the averted productivity loss to the UK economy would be between approximately £292 million (£197-£381 million) and £613 million (£424-£801 million) ( Table 7) .
Industry costs
The maximum discounted cost to industry over this period could be approximately £140 million, while the minimum whereby reformulation was absorbed into the natural product reformulation cycle would be £0 (Table 8) .
Cost effectiveness
Cost per LYG ranged across the four scenarios (S1 file table 10, Fig. 1 ) from approximately £1400 (£1424-£1469) in scenario 2 (to approximately £3100 (£3071-£3162) in scenario 3. In aggregate form, the intervention was most cost effective in middle aged men (55-74) at approximately £900/LYG; whilst it was the least cost effective in young women aged <55 years at approximately £6600 (Fig. 2) . Results are rounded to nearest £100 000 Table 5 Estimated discounted direct healthcare savings over the 10-year (2011-2020) period for scenarios 1, 2 and 3.
Healthcare savings Mean lci uci
Scenario 1 £191 000 000 £155 000 000 £228 000 000
Scenario 2 £201 000 000 £139 000 000 £262 000 000
Scenario 3 £95 000 000 £64 000 000 £125 000 000
Scenario 4 £105 000 000 £72 000 000 £137 000 000
The lower (lci) and upper confidence (uci) intervals are derived from 5%
and 95% centiles of 10 000 Monte Carlo simulations. Since many input variables are not normally distributed the CI may not be symmetrical.
Results are rounded to nearest £1 000 000 Informal care saving Mean lci uci Scenario 1 £727 000 000 £598 000 000 £880 000 000
Scenario 2 £557 000 000 £386 000 000 £728 000 000
Scenario 3 £368 000 000 £249 000 000 £481 000 000
Scenario 4 £409 000 000 £280 000 000 £531 000 000
The lower (lci) and upper confidence (uci) intervals are derived from 5 to 95% centiles of 10 000 Monte Carlo simulations. Since many input variables are not normally distributed the CI may not be symmetrical. Results are rounded to nearest £1 000 000 Table 7 Estimated discounted averted productivity loss over the 13-year (2007-2020) period for scenarios 1, 2, 3 and 4.
Productivity loss averted Mean lci Uci
Scenario 1 £583 000 000 £473 000 000 £697 000 000 Scenario 2 £613 000 000 £424 000 000 £801 000 000
Scenario 3 £292 000 000 £197 000 000 £381 000 000 Scenario 4 £322 000 000 £220 000 000 £418 000 000
The lower (lci) and upper confidence (uci) intervals are derived from 5 to 95% centiles of 10 000 Monte Carlo simulations. Since many input variables are not normally distributed the CI may not be symmetrical. Results are rounded to nearest £1 000 000 Table 8 Minimum and maximum industry costs in year 1, and discounted over the 10-year period.
Initial reformulation
Period cost Ongoing annual cost
Period cost
Maximum £200 000 000 £142 000 000 £2 000 000 £14 000 000
Results are rounded to nearest £1 000 000
The cost per LYG also varies substantially across SEC. Unsurprisingly; the policy was most cost effective in the most deprived quintile with an aggregate cost per LYG of approximately £1200 (£1148-£1218), compared with £2100 (£2004-£2133) per LYG in the most affluent in scenario 1 (elimination of al TFA, equal intake). As expected, this difference is even larger in scenario 2 (elimination of all TFA, unequal intake) (Fig. 1, Table 10 , Supplementary data). The cost-effectiveness plane (Fig. 3) demonstrates each scenario to be both cost saving and gain life years in each iteration of the uncertainty analysis. Furthermore, this policy could generate between approximately 8900 (scenario 3) and 19 300 (scenario 2) QALYs over the 10-year period. As these policies are cost saving, this is the dominating policy against the baseline.
Discussion
Main finding A UK-wide elimination of all TFA could result in substantial health gains and NHS savings. While mortality gains would be greatest in the elderly, a large number of life years would be gained in the younger age groups (Table 9 ).
All TFA policies modelled would be cost-effective; however, elimination of all TFA could be 'extremely cost effective' (a WHO definition for policies costing less than per capita GDP). This model suggests that elimination of all TFA would be more effective than the baseline (no ban) and cost saving, hence the dominant scenario. A comparison of 30 when taking a 10-year view (as in our study) estimates cost-effectiveness of statins varied from £36 000-£286 000 per QALY for those aged 45 years, increasing to £53 000-£367 000 per QALY for those aged 85 years. Even in the conservative scenario of calculating cost per QALY using costs only, each QALY would only cost £1300 (scenario 2) to £2800 (scenario 3).
Socioeconomic inequalities
The effect upon CHD inequalities could be substantial, with five times greater reduction in deaths and LYG in the most deprived groups, than the most affluent. This policy would be most cost-effective in the least affluent groups. Furthermore, the individual economic benefits, such as less time out of the workforce, and lower rates of early retirement due to ill health are not modelled here but would likely be substantial.
What is already known on this topic
Our health and cost-effectiveness outcomes results are consistent with previous studies. Mozaffarian et al. 31 analysed TFA consumption in Iran. Baseline intake of trans fats was five to six times above effective elimination, than in the UK, while baseline CHD mortality rates were also higher. This study suggested that elimination of industrial TFA could prevent 5600-27 300 CHD deaths. These modelling results are also consistent with the large (50%) reductions in CHD mortality observed in Denmark where TFA intake has been reduced from 6 to 1 g per day 22 as well as estimates made in the NICE guidelines of a potential 4500-7000 lives saved by reducing TFA in the UK. 32 Barton et al. 33 proposed that a 0.5% reduction in TFA intake (as a percentage of daily energy intake) might save approximately 2700 deaths and £235 million annually and gain 754 000 QALYS over a decade. However, this analysis did not take into account costs incurred in introducing and monitoring a policy, nor any industry costs.
What this study adds
Our study has implications for policy and future research. Firstly, the policy could save lives, money and reduce CHD inequalities. Importantly, cost-effectiveness can be compared with healthcare policies across several countries due to reporting in PPP dollars.
Strengths and limitations
This modelling study has several strengths. The modelling uses large data sets that cover the entire England and Wales adult population of 35 million. Data quality is generally very good. 23, [34] [35] [36] Furthermore, this study includes a wide range of potential cost sources including government and industry costs, while also accounting for cost savings in healthcare, informal care and productivity, as well as reporting several costeffectiveness measures. The data sets used are representative of the SEC distribution of the English and Welsh population.
This study also has several limitations. We used an area level categorization of SEC (IMD). This might therefore be considered sub optimal for analysing trends within individuals but generally correlates well with measures of individual socioeconomic position. 23 Furthermore, this model assumes immediate health benefits. However, rapid improvements might reasonably be expected. 37 While the scenarios eliminating industrial TFA only (3 and 4) model an elimination of industrial TFA, scenarios 1 and 2 model a total elimination of TFA, including ruminant TFA. The harmful effects of ruminant TFA are less well documented than industrial TFA; however, this is now less clear. 7 We assume equal mortality gains from ruminant elimination as industrial. This scenario is useful to quantify the total disease burden, however is a politically idealistic target, more feasible in vegan populations than the general population. Reformulation cost estimates range greatly, while the Danish Veterinary and Food Administration understood the reformulation costs to the industry to be negligible. 26 We therefore modelled best and worst case scenarios for these cost estimates.
Conclusions
This study provides quantitative health and economic measures, to better inform policymakers. Population-based prevention policies such as eliminating industrial TFA may generate substantial health and inequalities gains, as well as economic savings. The case for primary prevention policies has never been stronger.
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